Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan‐cancer analysis
Published 2020 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Spectrum of EGFR aberrations and potential clinical implications: insights from integrative pan‐cancer analysis
Authors
Keywords
-
Journal
Cancer Communications
Volume -, Issue -, Pages -
Publisher
Wiley
Online
2020-02-18
DOI
10.1002/cac2.12005
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Beyond EGFR Targeting in SCCHN: Angiogenesis, PI3K, and Other Molecular Targets
- (2019) Esma Saada-Bouzid et al. Frontiers in Oncology
- The addition of cetuximab to preoperative chemoradiotherapy for locally advanced esophageal squamous cell carcinoma is associated with high rate of long term survival: Mature results from a prospective phase Ib/II trial
- (2019) Baruch Brenner et al. RADIOTHERAPY AND ONCOLOGY
- Epidermal growth factor receptor and EGFRvIII in glioblastoma: signaling pathways and targeted therapies
- (2018) Zhenyi An et al. ONCOGENE
- Prognostic significance of epidermal growth factor receptor expression in glioma patients
- (2018) Junhong Li et al. OncoTargets and Therapy
- Targeted therapies in the management of locally advanced and metastatic pancreatic cancer: a systematic review
- (2018) Anjali V. Sheahan et al. Oncotarget
- A subset of esophageal squamous cell carcinoma patient-derived xenografts respond to cetuximab, which is predicted by high EGFR expression and amplification
- (2018) Hanting Zhu et al. Journal of Thoracic Disease
- Biomarker panel predicts survival after resection in pancreatic ductal adenocarcinoma: A multi-institutional cohort study
- (2018) Christopher B. Nahm et al. EJSO
- Necitumumab for the treatment of advanced non-small-cell lung cancer
- (2018) Asunción Díaz-Serrano et al. Future Oncology
- The Pfam protein families database in 2019
- (2018) Sara El-Gebali et al. NUCLEIC ACIDS RESEARCH
- Small molecule inhibitors targeting the EGFR/ErbB family of protein-tyrosine kinases in human cancers
- (2018) Robert Roskoski PHARMACOLOGICAL RESEARCH
- A comprehensive review of uncommon EGFR mutations in patients with non-small cell lung cancer
- (2017) Hai-Yan Tu et al. LUNG CANCER
- GEPIA: a web server for cancer and normal gene expression profiling and interactive analyses
- (2017) Zefang Tang et al. NUCLEIC ACIDS RESEARCH
- Characterization of common and rare mutations in EGFR and associated clinicopathological features in a large population of Chinese patients with lung cancer
- (2017) Bing Wei et al. PATHOLOGY RESEARCH AND PRACTICE
- Correlation of EGFR-expression with safety and efficacy outcomes in SQUIRE: a randomized, multicenter, open-label, phase III study of gemcitabine–cisplatin plus necitumumab versus gemcitabine–cisplatin alone in the first-line treatment of patients with stage IV squamous non-small-cell lung cancer
- (2016) L. Paz-Ares et al. ANNALS OF ONCOLOGY
- Peptides Targeting EGF Block the EGF-EGFR Interaction
- (2016) Salvador Guardiola et al. CHEMBIOCHEM
- The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
- (2016) Yue-Lun Zhang et al. Oncotarget
- Standards and guidelines for the interpretation of sequence variants: a joint consensus recommendation of the American College of Medical Genetics and Genomics and the Association for Molecular Pathology
- (2015) Sue Richards et al. GENETICS IN MEDICINE
- Combined anti-Galectin-1 and anti-EGFR siRNA-loaded chitosan-lipid nanocapsules decrease temozolomide resistance in glioblastoma: In vivo evaluation
- (2015) Fabienne Danhier et al. INTERNATIONAL JOURNAL OF PHARMACEUTICS
- Clinical activity of afatinib in patients with advanced non-small-cell lung cancer harbouring uncommon EGFR mutations: a combined post-hoc analysis of LUX-Lung 2, LUX-Lung 3, and LUX-Lung 6
- (2015) James C-H Yang et al. LANCET ONCOLOGY
- A decade of EGFR inhibition in EGFR-mutated non small cell lung cancer (NSCLC): Old successes and future perspectives
- (2015) Alessandro Russo et al. Oncotarget
- Large-Scale Computational Screening Identifies First in Class Multitarget Inhibitor of EGFR Kinase and BRD4
- (2015) Bryce K. Allen et al. Scientific Reports
- Epidermal Growth Factor Receptor in Glioma: Signal Transduction, Neuropathology, Imaging, and Radioresistance
- (2015) Kimmo J. Hatanpaa et al. NEOPLASIA
- Effectiveness of Gefitinib against Non–Small-Cell Lung Cancer with the Uncommon EGFR Mutations G719X and L861Q
- (2014) Satoshi Watanabe et al. Journal of Thoracic Oncology
- Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial
- (2014) Yi-Long Wu et al. LANCET ONCOLOGY
- Challenges to targeting epidermal growth factor receptor in glioblastoma: escape mechanisms and combinatorial treatment strategies
- (2014) P. Roth et al. NEURO-ONCOLOGY
- Epidermal growth factor receptor targeting in cancer: A review of trends and strategies
- (2013) Chetan Yewale et al. BIOMATERIALS
- The Cancer Genome Atlas Pan-Cancer analysis project
- (2013) John N Weinstein et al. NATURE GENETICS
- Integrative Analysis of Complex Cancer Genomics and Clinical Profiles Using the cBioPortal
- (2013) J. Gao et al. Science Signaling
- Paradoxical Relationship Between the Degree of EGFR Amplification and Outcome in Glioblastomas
- (2012) Jonathan Hobbs et al. AMERICAN JOURNAL OF SURGICAL PATHOLOGY
- Dual Targeting of EGFR and HER3 with MEHD7945A Overcomes Acquired Resistance to EGFR Inhibitors and Radiation
- (2012) S. Huang et al. CANCER RESEARCH
- The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
- (2012) Antonella De Luca et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
- (2012) Rafael Rosell et al. LANCET ONCOLOGY
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- Molecular Characteristics and Pathways of Avastin for the Treatment of Glioblastoma Multiforme
- (2012) Marko Spasic et al. NEUROSURGERY CLINICS OF NORTH AMERICA
- The cBio Cancer Genomics Portal: An Open Platform for Exploring Multidimensional Cancer Genomics Data: Figure 1.
- (2012) Ethan Cerami et al. Cancer Discovery
- Effectiveness of Tyrosine Kinase Inhibitors on "Uncommon" Epidermal Growth Factor Receptor Mutations of Unknown Clinical Significance in Non-Small Cell Lung Cancer
- (2011) J.-Y. Wu et al. CLINICAL CANCER RESEARCH
- Cell Signaling by Receptor Tyrosine Kinases
- (2010) Mark A. Lemmon et al. CELL
- International network of cancer genome projects
- (2010) Thomas J. Hudson (Chairperson) et al. NATURE
- Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR
- (2010) Makoto Maemondo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer
- (2009) Michael J. Eck et al. BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS
- Functional Analysis of Epidermal Growth Factor Receptor (EGFR) Mutations and Potential Implications for EGFR Targeted Therapy
- (2009) R. K. Kancha et al. CLINICAL CANCER RESEARCH
- Epidermal growth factor receptor in relation to tumor development: EGFR gene and cancer
- (2009) Tetsuya Mitsudomi et al. FEBS Journal
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now